FundraiseSep 11, 2026, 01:22 UTC

Genscript to raise $300M in share placing to scale AI drug discovery

What's the deal? Genscript Biotech, a Hong Kong-listed biotechnology company, has agreed to raise about HK$2.33 billion (roughly $300 million) through a discounted share placing. It will issue 77,126,000 new shares at HK$30.50 each to at least six professional or institutional investors.

The terms: The placing shares represent about 3.38% of the enlarged share capital and are priced at a single-digit discount to recent market prices. No investor is expected to become a substantial shareholder, and the shares are being issued under the company's existing general mandate.

What's the endgame? Genscript will use most of the net proceeds to expand capacity and infrastructure for its AI-driven drug discovery (AIDD) platform. The rest will fund R&D, digital workflow integration, global business development, and general corporate purposes.

What could go wrong? The deal remains subject to listing approval and the conditions of the placing agreement. Genscript cautioned that completion "may or may not materialize."

The context: Genscript, incorporated in the Cayman Islands and listed on the Stock Exchange of Hong Kong, carries a market capitalisation of HK$75.92 billion. Its AIDD platform is supported by automated high-throughput wet-lab facilities and digital workflows. The most recent analyst rating on the stock is a Buy, with a HK$30.00 price target.

The signal: The raise reflects the push among biotech firms to fund the capital-intensive infrastructure behind AI drug discovery, betting that automated, technology-heavy platforms can sharpen efficiency and strengthen their position in the sector.